Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction
Status:
Recruiting
Trial end date:
2020-08-15
Target enrollment:
Participant gender:
Summary
Percutaneous coronary intervention(PCI) has become the first choice for STEMI
patients.According to the current guidelines,dual antiplatelet therapy with a P2Y12 receptor
inhibitor and aspirin ,and intravenous injection of morphine therapy for chest pain relief in
necessity play a pivotal role in the treatment of patients with ST elevation myocardial
infarction before primary percutaneous coronary intervention.And ticagrelor is recommended in
patients with ST segment elevation myocardial infarction undergoing PCI, with class IB
indication.Therefore coadministration of morphine and ticagrelor are commonplace.Currently,
some studies have found that morphine delayed and attenuated exposure to ticagrelor,but it is
not clear of the pathogenesis of it.Some researchers say that morphine results in a weaker
and retarded antiplatelet effect of ticagrelor in STEMI patients before PCI by inhibition of
gastrointestinal peristalsis and causing vomiting.The study is aimed at exploring whether
morphine delay and attenuate exposure to ticagrelor and its antiplatelet effect.In addition,
the trial will explore the possible mechanism which morphne delay and attenuate exposure to
ticagrelor in patients with ST-segment elevation myocardial infarction before PCI.